BR112023000403A2 - Comprimido de desintegração oral, e, método para produzir um comprimido de desintegração oral - Google Patents

Comprimido de desintegração oral, e, método para produzir um comprimido de desintegração oral

Info

Publication number
BR112023000403A2
BR112023000403A2 BR112023000403A BR112023000403A BR112023000403A2 BR 112023000403 A2 BR112023000403 A2 BR 112023000403A2 BR 112023000403 A BR112023000403 A BR 112023000403A BR 112023000403 A BR112023000403 A BR 112023000403A BR 112023000403 A2 BR112023000403 A2 BR 112023000403A2
Authority
BR
Brazil
Prior art keywords
disintegration tablet
oral disintegration
producing
tablet
orally
Prior art date
Application number
BR112023000403A
Other languages
English (en)
Portuguese (pt)
Inventor
Yoshinaga Shinji
Nakahashi Toshiyuki
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112023000403A2 publication Critical patent/BR112023000403A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112023000403A 2020-07-27 2021-07-26 Comprimido de desintegração oral, e, método para produzir um comprimido de desintegração oral BR112023000403A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020126311 2020-07-27
PCT/JP2021/027505 WO2022024979A1 (ja) 2020-07-27 2021-07-26 ミロガバリンベシル酸塩を含有する口腔内崩壊錠

Publications (1)

Publication Number Publication Date
BR112023000403A2 true BR112023000403A2 (pt) 2023-02-07

Family

ID=80036359

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000403A BR112023000403A2 (pt) 2020-07-27 2021-07-26 Comprimido de desintegração oral, e, método para produzir um comprimido de desintegração oral

Country Status (6)

Country Link
JP (1) JP7744908B2 (https=)
KR (1) KR20230044355A (https=)
CN (1) CN115803020A (https=)
BR (1) BR112023000403A2 (https=)
TW (1) TWI883230B (https=)
WO (1) WO2022024979A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024248079A1 (https=) * 2023-06-02 2024-12-05
CN116966158B (zh) * 2023-08-14 2025-10-21 四川制药制剂有限公司 一种富马酸丙酚替诺福韦片的制备方法
CN118948808B (zh) * 2024-08-07 2025-11-25 山东大学 一种苯磺酸米洛巴林口溶膜剂及其制备方法
CN120437109B (zh) * 2025-07-09 2025-09-26 湖南一格制药有限公司 一种稳定性优异的苯磺酸美洛加巴林制剂组合物
CN121221543A (zh) * 2025-11-26 2025-12-30 华润双鹤利民药业（济南）有限公司 一种苯磺酸美洛加巴林口崩片制剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003034655A (ja) * 2001-05-15 2003-02-07 Takeda Chem Ind Ltd 速崩壊性固形製剤
US7390503B1 (en) * 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US8486450B2 (en) * 2005-12-28 2013-07-16 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
JP5295506B2 (ja) * 2006-02-21 2013-09-18 第一三共株式会社 レボフロキサシン含有錠剤
ES2393640T3 (es) * 2008-02-13 2012-12-26 Dainippon Sumitomo Pharma Co., Ltd. Comprimidos bucodisgregables
JP5308042B2 (ja) * 2008-03-11 2013-10-09 新田ゼラチン株式会社 マンゴー抽出物
JP5031054B2 (ja) * 2010-03-18 2012-09-19 信越化学工業株式会社 低置換度ヒドロキシプロピルセルロース及びこれを含む固形製剤
BR112014026292B1 (pt) * 2012-04-24 2022-09-27 Daiichi Sankyo Company, Limited Comprimido oralmente desintegrável, e, processo para a produção de um comprimido oralmente desintegrável
CN104334169B (zh) 2013-04-04 2016-11-02 第一三共株式会社 包含氨基羧酸盐的固体组合物
BR112017019920B1 (pt) 2015-03-19 2023-11-07 Daiichi Sankyo Company, Limited Preparação sólida farmacêutica, e, método para estabilização de uma preparação sólida farmacêutica
BR112017019918B1 (pt) 2015-03-19 2023-11-07 Daiichi Sankyo Company, Limited Preparação sólida farmacêutica, e, método para produzir uma preparação sólida farmacêutica para estabilizar uma preparação sólida farmacêutica
TWI812602B (zh) * 2016-12-01 2023-08-21 日商第一三共股份有限公司 含二胺衍生物之口腔崩散錠及其製造方法
JP7182356B2 (ja) * 2017-07-05 2022-12-02 日本ケミファ株式会社 口腔内崩壊錠及びその製造方法
JPWO2019021957A1 (ja) * 2017-07-25 2020-07-09 第一三共株式会社 点鼻用乾燥粉末医薬組成物
JP7148319B2 (ja) * 2017-08-17 2022-10-05 第一三共株式会社 プラスグレルを含む口腔内崩壊錠
BR112021001008A2 (pt) * 2018-07-30 2021-04-20 Daiichi Sankyo Company, Limited comprimido de fármaco
CN110742868A (zh) * 2019-11-20 2020-02-04 合肥拓锐生物科技有限公司 一种Mirogabalin Besilate口腔崩解片

Also Published As

Publication number Publication date
KR20230044355A (ko) 2023-04-04
JPWO2022024979A1 (https=) 2022-02-03
TWI883230B (zh) 2025-05-11
JP7744908B2 (ja) 2025-09-26
WO2022024979A1 (ja) 2022-02-03
CN115803020A (zh) 2023-03-14
TW202220643A (zh) 2022-06-01

Similar Documents

Publication Publication Date Title
BR112023000403A2 (pt) Comprimido de desintegração oral, e, método para produzir um comprimido de desintegração oral
MX2016007105A (es) Composiciones farmaceuticas que comprenden fumarato de dimetilo.
BR112022006202A2 (pt) Compostos heterocíclicos de arila como bloqueadores de canal do agitador de potássio kv1,3
EA201170960A1 (ru) Твердая фармацевтическая композиция, содержащая амлодипин и лозартан
MX2017014612A (es) Metodo para hacer celulosa microcristalina blanqueada.
BR112021022378A2 (pt) Derivado de tetraidroisoquinolina substituído como um modulador alostérico d1 positivo
MX2018005784A (es) Mezcla hemostatica de fibras cortas y largas basadas en celulosa.
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
MX383647B (es) Análogos deuterados de etifoxina, sus derivados y usos de estos.
BR112018014856A2 (pt) composição compreendendo farinha sem glúten e hidroxipropil metil celulose
PH12019501288A1 (en) Novel preparation containing benzimidazole derivative
BR112023001048A2 (pt) Agonista de ppar-delta cristalino
BRPI0519792A2 (pt) antagonistas do receptor 5-ht7
BR112018000839A2 (pt) processo para produzir uma suspensão aquosa de carbonato de cálcio precipitado, suspensão aquosa de carbonato de cálcio precipitado, carbonato de cálcio precipitado, produto, e, uso de uma suspensão aquosa de carbonato de cálcio precipitado e/ou de carbonato de cálcio precipitado.
MX384146B (es) Triple combinación de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.
BR112023012664A2 (pt) Método de produção de composição de resina contendo arroz, e amassador de parafuso duplo
BR112022006226A2 (pt) Compostos heterocíclicos de arilmetileno como bloqueadores de canal do agitador de potássio kv1,3
BR112023001585A2 (pt) Composto, e, composição farmacêutica para a prevenção ou tratamento de dor
BR112022007431A2 (pt) Composição de celulose e comprimido
AU2018313049A8 (en) Fluoropiperidine compounds as pure 5-HT6 receptor antagonists
DOP2023000199A (es) Formulación que comprende ceralasertib
BR112022004463A2 (pt) Aditivo de cimento biopolimérico
EA202092999A1 (ru) Противовирусная композиция
PH12021550451A1 (en) Novel composition of lapatinib of oral solid dosage form and method of manufacturing thereof
EA202191302A1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА Mcl-1 И МИДОСТАУРИНА, ЕЕ ПРИМЕНЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]